Many patients spend significant money on retail CBD products with doses far below therapeutic thresholds, creating frustration and skepticism about cannabis medicine’s efficacy. Understanding dosing gaps between consumer products and clinical evidence helps clinicians guide patients toward effective treatment options.
Retail CBD products like Wana gummies typically contain 5-25mg per dose, while published clinical trials for anxiety disorders generally study doses of 300-600mg daily. The therapeutic window for CBD in anxiety appears to require substantially higher doses than most commercial products provide. This dosing disconnect likely explains why many patients report minimal benefit from over-the-counter CBD products despite robust preclinical evidence for CBD’s anxiolytic properties.
“I regularly see patients who’ve tried CBD gummies for months without benefit, not realizing they’re taking one-twentieth of a potentially effective dose. The retail CBD market has created unrealistic expectations about what 10mg can accomplish for clinical anxiety.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
What is the clinical relevance rating of this cannabis news?
This article has been assigned CED Clinical Relevance #70, which indicates “Notable Clinical Interest.” This rating suggests the content contains emerging findings or policy developments that healthcare professionals should monitor closely.
What medical condition does this article focus on?
The article primarily focuses on anxiety disorders and their treatment. It appears to discuss the use of CBD (cannabidiol) as a potential therapeutic option for managing anxiety symptoms.
What specific aspect of CBD is being discussed?
The article addresses CBD dosing considerations for anxiety treatment. This likely includes recommendations for appropriate dosages, administration methods, and dosing protocols for patients using CBD therapeutically.
Does this article discuss consumer CBD products?
Yes, the article includes information about consumer CBD products available in the market. This may cover product quality, availability, and considerations for patients choosing between different CBD formulations.
Who is the target audience for this clinical information?
This information is primarily intended for healthcare professionals working in clinical settings. The CED Clinical Relevance rating system suggests it’s designed to help clinicians stay informed about important developments in cannabis medicine.
